Endpoints News reporter, Natalie Grover, writes about the recent Series A financing round that will fund Grey Wolf’s drug development program over the next 2-3 years, focused on a new immuno-oncology therapy, targeting tumour cells to illuminate them for attack and destruction by the immune system. Investors Canaan and Andera have shown their support for this potential new treatment for cancers. Read more
